Serotonergic perturbations can reveal relapse vulnerability and altered release capacity, but a simple baseline-deficiency account of all major depression requires evidence beyond antidepressant efficacy or candidate-gene association. State, subtype and measurement specificity remain central.
This dated addendum adds selected evidence and tests that could resolve the remaining questions. It does not regrade the archived review.
Each question identifies a limit in the checked evidence. A missing search result alone does not establish a gap in the entire field.
Competing explanation: Release differences may be state effects or downstream consequences of illness.
Discriminating test: Longitudinal never-medicated at-risk and incident-case cohorts with repeated validated release measurements, matched controls and treatment histories.
Competing explanation: Prior treatment and recurrent illness may create vulnerability distinct from initial causation.
Discriminating test: Prespecified comparisons of untreated acute, remitted medication-free and treated groups; sham crossover, depletion confirmation and symptom monitoring.
Competing explanation: Challenge pharmacology, tracer binding, receptor regulation or nonserotonergic effects may influence the signal.
Discriminating test: Independent replication with test–retest assessment and orthogonal measures; prespecify challenge/tracer controls and distinguish release from receptor density.
Competing explanation: Emotional processing and downstream network adaptation may improve symptoms without correcting a baseline deficit.
Discriminating test: Repeated mediators and clinical endpoints within randomized treatment comparisons; preserve timing and test competing noradrenergic/psychological pathways.
Electronic publication dates are used where recorded, with issue years shown separately. This is a selected chronology, not a claim of scientific priority or independent replication for every entry.
Tryptophan depletion transiently reversed remission in a subset.
What it cannot establish: Drug-maintained vulnerability does not establish low serotonin as the initial disease cause.
Rapid depletion did not immediately worsen depression; later responses varied.
What it cannot establish: The relation is not a simple linear deficiency-to-symptom function.
A serotonin-transporter genotype interaction with stress was reported.
What it cannot establish: A candidate-gene interaction is not a direct serotonin measurement and later large studies challenged the finding.
Depletion induced symptoms and altered regional metabolism in remitted patients versus controls.
What it cannot establish: Susceptibility after past disease is not prospective proof of an initiating deficiency.
Emotional-processing bias changed before subjective mood improved.
What it cannot establish: Noradrenergic treatment demonstrates a competing treatment route, not direct serotonin restoration.
Historical candidate-gene and interaction findings were not supported.
What it cannot establish: Null candidate variants do not directly measure or exclude every serotonergic mechanism.
Release capacity was lower in the studied depressive-episode group.
What it cannot establish: Small cross-sectional challenge study cannot establish temporal precedence or universal deficiency.
Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.
Primary abstract/metadata checked. Additional Consensus full-text details remain provider-reported because a separately readable body was unavailable in this update.
This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.
Selected full-text checks: 0; abstract checks: 7; metadata-only anchors: 0. Complete-paper examinations credited in this update: 0.
New enrichment: HSEF v5.3 causal distinctions. Archived scorecard schema: 5.4; retained as recorded.
This focused timeline contains seven distinct primary studies rather than padding the count with meta-analyses. An unrelated PMID returned during identifier verification was excluded.
PMID 2184795 · DOI 10.1001/archpsyc.1990.01810170011002
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 7944875 · DOI 10.1001/archpsyc.1994.03950110025005
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 12869766 · DOI 10.1126/science.1083968
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 15289275 · DOI 10.1001/archpsyc.61.8.765
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 19755572 · DOI 10.1176/appi.ajp.2009.09020149
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 30845820 · DOI 10.1176/appi.ajp.2018.18070881
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 36635177 · DOI 10.1016/j.biopsych.2022.10.012
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Read the dated addendum · Video script and storyboard insert · References (RIS) · References (BibTeX)